INDIANAPOLIS , July 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference. The webcast will be
Eli Lilly's prospective drugs and existing obesity/diabetes medicines are strong. The company's dividend has lots of room for growth.
Nathan Bomey, Axios Business Reporter and Co-author of the Axios Closer Newsletter, joins Yahoo Finance Live anchors Julie Hyman and Brad Smith to discuss the popularity of prescription weight loss dr
Eli Lilly has seen a massive ramp-up in its diabetes, or better said weight loss, drug Mounjaro. Investors continue to price in further advancements on this front; the question is how much is priced i
Stocks of developers of fatty liver disease treatments had been on a tear until results from Eli Lilly's medication were published last week.
Lilly (LLY) continues to raise the bar on obesity drugs as latest data show that participants treated with these experimental drugs achieved mean weight reduction of up to 24%.
Verve Therapeutics announced a partnership with Eli Lilly & Co., focusing on in-vivo gene editing technology, but investors remain concerned about the FDA's clinical hold on Verve's PCSK9 candidate VE
Eli Lilly is working on a molecule that might be better than Novo Nordisk's Ozempic. It already has another medicine on the market that could be better.
Eli Lilly and Company continues to make impressive progress when it comes to its obesity and diabetes medications. Shares have already shot up in recent months because of this, but this is likely the
Pharmaceutical stocks have not shared in this year's bull rally. Year to date, the S&P Pharmaceuticals Select Industry index is down 1% while the benchmark S&P 500 index has gained 15%.
Eli Lilly stock (NYSE: LLY) currently trades at $459 per share, roughly 150% above its level in March 2021.
Shares of Sigilon Therapeutics Inc (NASDAQ: SGTX) soared more than 500% today after Eli Lilly & Co (NYSE: LLY) said it will buy the biopharmaceutical company in a deal worth up to $309.6 million. Deta

Eli Lilly to Acquire Sigilon Therapeutics

12:55pm, Thursday, 29'th Jun 2023
Eli Lilly said it will acquire Sigilon Therapeutics in an all-cash deal worth up to $309.6 million.
Eli Lilly and Co (NYSE:LLY) shares are up again Thursday as its weight loss drug retatrutide continues to garner attention from investors and analysts alike.  UBS reiterated its Buy rating and $498
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE